Screener
Regeneron Pharmaceuticals REGN Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| (In millions) / As of June 30, 2026 | Amortized / Cost Basis | Unrealized / Gains | Unrealized / Losses | Fair / Value |
|---|---|---|---|---|
| Certificates of deposit | 304.4 | — | (0.3) | 304.1 |
| Asset-backed securities | 193.2 | 0.2 | (0.3) | 193.1 |
| Sovereign bonds | 78.5 | 0.1 | (0.3) | 78.3 |
| $15,220.7 | $21.0 | $(52.5) | $15,189.2 | |
| As of December 31, 2025 | ||||
| Corporate bonds | $10,141.0 | $80.9 | $(2.4) | $10,219.5 |
| U.S. government and government agency obligations | 4,352.2 | 15.2 | (0.1) | 4,367.3 |
| Commercial paper | 540.8 | 0.3 | — | 541.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's cumulative cost basis?
- Regeneron Pharmaceuticals (REGN) reported cumulative cost basis of $15.22B in Q2 2026.
- How has Regeneron Pharmaceuticals's cumulative cost basis changed year-over-year?
- Regeneron Pharmaceuticals's cumulative cost basis increased by 8.9% year-over-year, from $13.98B to $15.22B.
- What is the long-term trend for Regeneron Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's cumulative cost basis has grown at a 33.7% compound annual growth rate (CAGR), from $3.65B to $15.62B.
Ask your AI about Regeneron Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude